看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 51.1x - 56.5x | 53.8x |
| Selected Fwd P/E Multiple | 36.2x - 40.0x | 38.1x |
| Fair Value | ₹2,368 - ₹2,617 | ₹2,492 |
| Upside | -16.5% - -7.8% | -12.1% |
| Benchmarks | - | Full Ticker |
| Lupin Limited | 50,025,700.0% | BSE:500257 |
| Alembic Pharmaceuticals Limited | 53,357,300.0% | BSE:533573 |
| Medico Remedies Limited | 54,093,700.0% | BSE:540937 |
| Zydus Lifesciences Limited | 53,232,100.0% | BSE:532321 |
| Glenmark Pharmaceuticals Limited | 53,229,600.0% | BSE:532296 |
| GlaxoSmithKline Pharmaceuticals Limited | - | NSEI:GLAXO |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| 500257 | 533573 | 540937 | 532321 | 532296 | GLAXO | |||
| BSE:500257 | BSE:533573 | BSE:540937 | BSE:532321 | BSE:532296 | NSEI:GLAXO | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 30.2% | 1.1% | 39.5% | 15.7% | NM- | 5.8% | ||
| 3Y CAGR | 16.3% | -18.7% | 47.4% | 20.3% | NM- | 27.1% | ||
| Latest Twelve Months | 60.2% | 2.5% | 27.2% | 53.4% | 73.8% | 62.4% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 3.0% | 12.3% | 4.0% | 18.1% | 3.5% | 20.9% | ||
| Prior Fiscal Year | 2.6% | 6.1% | 5.2% | 11.4% | -1.5% | 18.7% | ||
| Latest Fiscal Year | 9.6% | 9.9% | 5.7% | 19.6% | -15.0% | 17.1% | ||
| Latest Twelve Months | 13.0% | 9.4% | 5.9% | 20.4% | -1.4% | 23.2% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 18.1x | 19.4x | 31.1x | 14.3x | 13.6x | 42.1x | ||
| Price / LTM Sales | 4.2x | 2.8x | 2.5x | 4.0x | 3.0x | 12.8x | ||
| LTM P/E Ratio | 31.9x | 29.4x | 43.0x | 19.6x | -208.6x | 55.0x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -208.6x | 29.4x | 43.0x | |||||
| Historical LTM P/E Ratio | 50.6x | 55.2x | 206.9x | |||||
| Selected P/E Multiple | 51.1x | 53.8x | 56.5x | |||||
| (x) LTM Net Income | 8,592 | 8,592 | 8,592 | |||||
| (=) Equity Value | 439,401 | 462,527 | 485,653 | |||||
| (/) Shares Outstanding | 169.4 | 169.4 | 169.4 | |||||
| Implied Value Range | 2,593.77 | 2,730.29 | 2,866.80 | |||||
| FX Rate: INR/INR | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 2,593.77 | 2,730.29 | 2,866.80 | 2,836.90 | ||||
| Upside / (Downside) | -8.6% | -3.8% | 1.1% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 500257 | 533573 | 540937 | 532321 | 532296 | GLAXO | |
| Value of Common Equity | 921,847 | 182,981 | 3,781 | 896,605 | 429,138 | 480,588 | |
| (/) Shares Outstanding | 456.5 | 196.6 | 83.0 | 1,006.2 | 282.2 | 169.4 | |
| Implied Stock Price | 2,019.20 | 930.90 | 45.56 | 891.05 | 1,520.75 | 2,836.90 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 2,019.20 | 930.90 | 45.56 | 891.05 | 1,520.75 | 2,836.90 | |
| Trading Currency | INR | INR | INR | INR | INR | INR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |